{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:49:38Z","timestamp":1792097378560,"version":"4.4.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"28","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"NIH\/NIAID","award":["R41AI073064"],"award-info":[{"award-number":["R41AI073064"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.vaccine.2011.04.045","type":"journal-article","created":{"date-parts":[[2011,5,8]],"date-time":"2011-05-08T14:17:00Z","timestamp":1304864220000},"page":"4638-4645","source":"Crossref","is-referenced-by-count":20,"title":["Immunization of mice with the non-toxic HC50 domain of botulinum neurotoxin presented by rabies virus particles induces a strong immune response affording protection against high-dose botulinum neurotoxin challenge"],"prefix":"10.1016","volume":"29","author":[{"given":"Waleed","family":"Mustafa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fetweh H.","family":"Al-Saleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zidoon","family":"Nasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca M.","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Mattis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lance L.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias J.","family":"Schnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2011.04.045_bib0005","first-page":"55","article-title":"Botulism: the present status of the disease","volume":"195","author":"Hatheway","year":"1995","journal-title":"Curr Top Microbiol Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2011.04.045_bib0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/10408410590912952","article-title":"Clostridium botulinum: a bug with beauty and weapon","volume":"31","author":"Shukla","year":"2005","journal-title":"Crit Rev Microbiol"},{"issue":"November (11)","key":"10.1016\/j.vaccine.2011.04.045_bib0015","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0968-0004(02)02177-1","article-title":"Botulinum and tetanus neurotoxins: structure, function and therapeutic utility","volume":"27","author":"Turton","year":"2002","journal-title":"Trends Biochem Sci"},{"issue":"February (8)","key":"10.1016\/j.vaccine.2011.04.045_bib0020","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/jama.285.8.1059","article-title":"Botulinum toxin as a biological weapon: medical and public health management","volume":"285","author":"Arnon","year":"2001","journal-title":"JAMA"},{"issue":"April (2)","key":"10.1016\/j.vaccine.2011.04.045_bib0025","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1152\/physrev.2000.80.2.717","article-title":"Neurotoxins affecting neuroexocytosis","volume":"80","author":"Schiavo","year":"2000","journal-title":"Physiol Rev"},{"key":"10.1016\/j.vaccine.2011.04.045_bib0030","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1146\/annurev.pharmtox.44.101802.121554","article-title":"Identification of the major steps in botulinum toxin action","volume":"44","author":"Simpson","year":"2004","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"March (13\u201314)","key":"10.1016\/j.vaccine.2011.04.045_bib0035","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/S0264-410X(98)00447-2","article-title":"Rabies \u2013 risk of exposure and current trends in prevention of human cases","volume":"17","author":"Haupt","year":"1999","journal-title":"Vaccine"},{"issue":"May\u2013Jun (3)","key":"10.1016\/j.vaccine.2011.04.045_bib0040","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/clinids\/2.3.433","article-title":"Rabies vaccine prepared in human cell cultures: progress and perspectives","volume":"2","author":"Plotkin","year":"1980","journal-title":"Rev Infect Dis"},{"issue":"June (3)","key":"10.1016\/j.vaccine.2011.04.045_bib0045","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1006\/clin.1994.1088","article-title":"Long-term humoral and cellular immunity after vaccination with cell culture rabies vaccines in man","volume":"71","author":"Thraenhart","year":"1994","journal-title":"Clin Immunol Immunopathol"},{"issue":"April (2)","key":"10.1016\/j.vaccine.2011.04.045_bib0050","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2174\/1570162033485320","article-title":"Recombinant rhabdoviruses as potential vaccines for HIV-1 and other diseases","volume":"1","author":"McKenna","year":"2003","journal-title":"Curr HIV Res"},{"issue":"March (7)","key":"10.1016\/j.vaccine.2011.04.045_bib0055","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1073\/pnas.97.7.3544","article-title":"Recombinant rabies virus as potential live-viral vaccines for HIV-1","volume":"97","author":"Schnell","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2011.04.045_bib0060","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1006\/viro.2001.1212","article-title":"Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines","volume":"292","author":"Siler","year":"2002","journal-title":"Virology"},{"issue":"September (2)","key":"10.1016\/j.vaccine.2011.04.045_bib0065","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.virol.2006.05.010","article-title":"Rabies virus glycoprotein as a carrier for anthrax protective antigen","volume":"353","author":"Smith","year":"2006","journal-title":"Virology"},{"issue":"May (10)","key":"10.1016\/j.vaccine.2011.04.045_bib0070","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1084\/jem.185.10.1785","article-title":"Role of repetitive antigen patterns for induction of antibodies against antibodies","volume":"185","author":"Fehr","year":"1997","journal-title":"J Exp Med"},{"issue":"November (11)","key":"10.1016\/j.vaccine.2011.04.045_bib0075","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.1002\/1521-4141(200211)32:11<3305::AID-IMMU3305>3.0.CO;2-J","article-title":"Regulation of IgG antibody responses by epitope density and CD21-mediated costimulation","volume":"32","author":"Jegerlehner","year":"2002","journal-title":"Eur J Immunol"},{"issue":"November (23)","key":"10.1016\/j.vaccine.2011.04.045_bib0080","doi-asserted-by":"crossref","first-page":"10908","DOI":"10.1073\/pnas.91.23.10908","article-title":"Rabies ribonucleocapsid as an oral immunogen and immunological enhancer","volume":"91","author":"Hooper","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"issue":"June (19\u201320)","key":"10.1016\/j.vaccine.2011.04.045_bib0085","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1016\/S0264-410X(02)00157-3","article-title":"Production and immunogenic efficacy of botulinum tetravalent (A, B, E, F) toxoid","volume":"20","author":"Torii","year":"2002","journal-title":"Vaccine"},{"issue":"March","key":"10.1016\/j.vaccine.2011.04.045_bib0090","doi-asserted-by":"crossref","first-page":"277","DOI":"10.4049\/jimmunol.88.3.277","article-title":"Studies on immunity to toxins of Clostridium botulinum. VIII. Immunological response of man to purified bivalent AB botulinum toxoid","volume":"88","author":"Fiock","year":"1962","journal-title":"J Immunol"},{"issue":"May","key":"10.1016\/j.vaccine.2011.04.045_bib0095","doi-asserted-by":"crossref","first-page":"697","DOI":"10.4049\/jimmunol.90.5.697","article-title":"Studies on immunity to toxins of Clostridium Botulinum, Ix. Immunologic response of man to purified pentavalent Abcde Botulinum toxiod","volume":"90","author":"Fiock","year":"1963","journal-title":"J Immunol"},{"issue":"August (1)","key":"10.1016\/j.vaccine.2011.04.045_bib0100","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jim.2008.05.009","article-title":"An improved method for development of toxoid vaccines and antitoxins","volume":"337","author":"Jones","year":"2008","journal-title":"J Immunol Methods"},{"issue":"September (9)","key":"10.1016\/j.vaccine.2011.04.045_bib0105","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1128\/CVI.00117-08","article-title":"Characterization of new formalin-detoxified botulinum neurotoxin toxoids","volume":"15","author":"Keller","year":"2008","journal-title":"Clin Vaccine Immunol"},{"issue":"October (10)","key":"10.1016\/j.vaccine.2011.04.045_bib0110","doi-asserted-by":"crossref","first-page":"6998","DOI":"10.1128\/IAI.73.10.6998-7005.2005","article-title":"Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E","volume":"73","author":"Baldwin","year":"2005","journal-title":"Infect Immun"},{"issue":"March (3)","key":"10.1016\/j.vaccine.2011.04.045_bib0115","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1128\/IAI.01025-07","article-title":"Subunit vaccine against the seven serotypes of botulism","volume":"76","author":"Baldwin","year":"2008","journal-title":"Infect Immun"},{"issue":"May (21)","key":"10.1016\/j.vaccine.2011.04.045_bib0120","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1016\/j.vaccine.2009.02.091","article-title":"The recombinant Hc subunit of Clostridium botulinum neurotoxin serotype A is an effective botulism vaccine candidate","volume":"27","author":"Yu","year":"2009","journal-title":"Vaccine"},{"issue":"July (23)","key":"10.1016\/j.vaccine.2011.04.045_bib0125","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1016\/S0264-410X(03)00260-3","article-title":"DNA vaccination protects against botulinum neurotoxin type F","volume":"21","author":"Bennett","year":"2003","journal-title":"Vaccine"},{"issue":"September (29\u201330)","key":"10.1016\/j.vaccine.2011.04.045_bib0130","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1016\/j.vaccine.2004.04.006","article-title":"Efficacy of DNA vaccines expressing the type F botulinum toxin Hc fragment using different promoters","volume":"22","author":"Jathoul","year":"2004","journal-title":"Vaccine"},{"issue":"September (9)","key":"10.1016\/j.vaccine.2011.04.045_bib0135","doi-asserted-by":"crossref","first-page":"5709","DOI":"10.1128\/IAI.69.9.5709-5715.2001","article-title":"Candidate vaccine against botulinum neurotoxin serotype A derived from a Venezuelan equine encephalitis virus vector system","volume":"69","author":"Lee","year":"2001","journal-title":"Infect Immun"},{"issue":"November (47\u201348)","key":"10.1016\/j.vaccine.2011.04.045_bib0140","doi-asserted-by":"crossref","first-page":"6886","DOI":"10.1016\/j.vaccine.2006.06.004","article-title":"Multiagent vaccines vectored by Venezuelan equine encephalitis virus replicon elicits immune responses to Marburg virus and protection against anthrax and botulinum neurotoxin in mice","volume":"24","author":"Lee","year":"2006","journal-title":"Vaccine"},{"issue":"December (52)","key":"10.1016\/j.vaccine.2011.04.045_bib0145","doi-asserted-by":"crossref","first-page":"8843","DOI":"10.1016\/j.vaccine.2007.10.016","article-title":"Enhanced immune responses using plasmid DNA replicon vaccine encoding the Hc domain of Clostridium botulinum neurotoxin serotype A","volume":"25","author":"Yu","year":"2007","journal-title":"Vaccine"},{"issue":"October (43)","key":"10.1016\/j.vaccine.2011.04.045_bib0150","doi-asserted-by":"crossref","first-page":"7540","DOI":"10.1016\/j.vaccine.2007.08.035","article-title":"Protective immunity against botulism provided by a single dose vaccination with an adenovirus-vectored vaccine","volume":"25","author":"Zeng","year":"2007","journal-title":"Vaccine"},{"issue":"March (3)","key":"10.1016\/j.vaccine.2011.04.045_bib0155","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/gt.2008.181","article-title":"An adenoviral vector-based mucosal vaccine is effective in protection against botulism","volume":"16","author":"Xu","year":"2009","journal-title":"Gene Ther"},{"issue":"March (11\u201312)","key":"10.1016\/j.vaccine.2011.04.045_bib0160","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/S0264-410X(02)00622-9","article-title":"Vaccination against type F botulinum toxin using attenuated Salmonella enterica var Typhimurium strains expressing the BoNT\/F H(C) fragment","volume":"21","author":"Foynes","year":"2003","journal-title":"Vaccine"},{"issue":"August (2)","key":"10.1016\/j.vaccine.2011.04.045_bib0165","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1124\/jpet.104.066845","article-title":"Structural features of the botulinum neurotoxin molecule that govern binding and transcytosis across polarized human intestinal epithelial cells","volume":"310","author":"Maksymowych","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"issue":"September (18)","key":"10.1016\/j.vaccine.2011.04.045_bib0170","doi-asserted-by":"crossref","first-page":"8724","DOI":"10.1128\/JVI.75.18.8724-8732.2001","article-title":"Expression and immunogenicity of human immunodeficiency virus type 1 Gag expressed by a replication-competent rhabdovirus-based vaccine vector","volume":"75","author":"McGettigan","year":"2001","journal-title":"J Virol"},{"issue":"December (23)","key":"10.1016\/j.vaccine.2011.04.045_bib0175","doi-asserted-by":"crossref","first-page":"11496","DOI":"10.1128\/JVI.75.23.11496-11502.2001","article-title":"Extensive attenuation of rabies virus by simultaneously modifying the dynein light chain binding site in the P protein and replacing Arg333 in the G protein","volume":"75","author":"Mebatsion","year":"2001","journal-title":"J Virol"},{"issue":"December (26)","key":"10.1016\/j.vaccine.2011.04.045_bib0180","doi-asserted-by":"crossref","first-page":"14680","DOI":"10.1073\/pnas.011510698","article-title":"A recombinant rabies virus expressing vesicular stomatitis virus glycoprotein fails to protect against rabies virus infection","volume":"97","author":"Foley","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"10.1016\/j.vaccine.2011.04.045_bib0185","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/0041-0101(84)90085-0","article-title":"Purification and amino acid composition of type A botulinum neurotoxin","volume":"22","author":"DasGupta","year":"1984","journal-title":"Toxicon"},{"issue":"2","key":"10.1016\/j.vaccine.2011.04.045_bib0190","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0163-7258(82)90061-4","article-title":"Clostridium botulinum toxins","volume":"19","author":"Sakaguchi","year":"1982","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.vaccine.2011.04.045_bib0195","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0076-6879(88)65015-4","article-title":"Isolation and characterization of the Botulinum neurotoxins","volume":"165","author":"Simpson","year":"1988","journal-title":"Methods Enzymol"},{"issue":"August (5259)","key":"10.1016\/j.vaccine.2011.04.045_bib0200","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/227680a0","article-title":"Cleavage of structural proteins during the assembly of the head of bacteriophage T4","volume":"227","author":"Laemmli","year":"1970","journal-title":"Nature"},{"issue":"June (6)","key":"10.1016\/j.vaccine.2011.04.045_bib0205","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1128\/IAI.01893-06","article-title":"Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route","volume":"75","author":"Ravichandran","year":"2007","journal-title":"Infect Immun"},{"issue":"September\u2013October (9\u201310)","key":"10.1016\/j.vaccine.2011.04.045_bib0210","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0300-9084(00)01173-1","article-title":"Development of vaccines for prevention of botulism","volume":"82","author":"Byrne","year":"2000","journal-title":"Biochimie"},{"issue":"October (10)","key":"10.1016\/j.vaccine.2011.04.045_bib0215","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1128\/IAI.66.10.4817-4822.1998","article-title":"Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate","volume":"66","author":"Byrne","year":"1998","journal-title":"Infect Immun"},{"issue":"July (7)","key":"10.1016\/j.vaccine.2011.04.045_bib0220","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1128\/IAI.63.7.2738-2742.1995","article-title":"Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli","volume":"63","author":"Clayton","year":"1995","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2011.04.045_bib0225","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1146\/annurev.immunol.21.120601.141045","volume":"21","author":"Zinkernagel","year":"2003","journal-title":"Annu Rev Immunol"},{"issue":"August","key":"10.1016\/j.vaccine.2011.04.045_bib0230","first-page":"171","article-title":"A two-phase model of B-cell activation","volume":"176","author":"Baumgarth","year":"2000","journal-title":"Immunol Rev"},{"issue":"October (10)","key":"10.1016\/j.vaccine.2011.04.045_bib0235","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/0041-0101(95)00072-T","article-title":"Expression of a large, nontoxic fragment of botulinum neurotoxin serotype A and its use as an immunogen","volume":"33","author":"LaPenotiere","year":"1995","journal-title":"Toxicon"},{"key":"10.1016\/j.vaccine.2011.04.045_bib0240","series-title":"The natural history of rabies","first-page":"31","article-title":"The chemical composition and molecular structure of rabies viruses","author":"Wunner","year":"1991"},{"issue":"3","key":"10.1016\/j.vaccine.2011.04.045_bib0245","first-page":"219","article-title":"Structure, activity, and immune (T and B cell) recognition of botulinum neurotoxins","volume":"19","author":"Atassi","year":"1999","journal-title":"Crit Rev Immunol"},{"issue":"May (5)","key":"10.1016\/j.vaccine.2011.04.045_bib0250","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1128\/IAI.65.5.1626-1630.1997","article-title":"Antibody mapping to domains of botulinum neurotoxin serotype A in the complexed and uncomplexed forms","volume":"65","author":"Chen","year":"1997","journal-title":"Infect Immun"},{"issue":"October (14)","key":"10.1016\/j.vaccine.2011.04.045_bib0255","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S0161-5890(97)00107-7","article-title":"Immune recognition of botulinum neurotoxin type A: regions recognized by T cells and antibodies against the protective H(C) fragment (residues 855\u20131296) of the toxin","volume":"34","author":"Oshima","year":"1997","journal-title":"Mol Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11005901?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11005901?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T17:24:14Z","timestamp":1686072254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X11005901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":51,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S0264410X11005901"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2011.04.045","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]}}}